Antinociceptive activity of standardized extract of Bacopa monnieri in different pain models of zebrafish

2022 ◽  
Vol 282 ◽  
pp. 114546
Author(s):  
Mahima Sharma ◽  
Pankaj Kumar Gupta ◽  
Pankaj Gupta ◽  
Debapriya Garabadu
Keyword(s):  
Bacopa Monnieri ◽  
Antinociceptive Activity ◽  
Pain Models

Investigations into the antinociceptive activity ofSapindus trifoliatusin various pain models

2004 ◽  
Vol 56 (5) ◽  
pp. 655-661 ◽  
Author(s):  
D. K. Arulmozhi ◽  
A. Veeranjaneyulu ◽  
S. K. Arora ◽  
S. L. Bodhankar
Keyword(s):  
Antinociceptive Activity ◽  
Pain Models

Lack of antinociceptive activity of clonidine in two pain models: Comparison with other analgesics and CNS active drugs

1984 ◽  
Vol 4 (2) ◽  
pp. 217-222 ◽  
Author(s):  
Theodore C. Spaulding ◽  
Minh G. Ma ◽  
Robert W. Dunn ◽  
Stuart Fielding
Keyword(s):  
Antinociceptive Activity ◽  
Pain Models ◽  
Models Comparison

Antinociceptive activity of intraperitoneally administered novel and potent anticonvulsive compound, CY-PROLL-SS, in animal neuropathic pain models

2016 ◽  
Vol 68 (3) ◽  
pp. 601-607 ◽  
Author(s):  
Magdalena Bujalska-Zadrożny ◽  
Ewelina Kogut ◽  
Anna de Cordé ◽  
Maciej Dawidowski ◽  
Patrycja Kleczkowska
Keyword(s):  
Neuropathic Pain ◽  
Antinociceptive Activity ◽  
Pain Models

scholarly journals The antinociceptive activity of harmicine on chemical-induced neurogenic and inflammatory pain models in mice

2012 ◽  
Vol 102 (1) ◽  
pp. 133-138 ◽  
Author(s):  
Humberto M. Spindola ◽  
Débora B. Vendramini-Costa ◽  
Manoel T. Rodrigues ◽  
Mary A. Foglio ◽  
Ronaldo A. Pilli ◽  
...  
Keyword(s):  
Inflammatory Pain ◽  
Antinociceptive Activity ◽  
Pain Models

The antinociceptive activity of Polygonatum verticillatum rhizomes in pain models

2010 ◽  
Vol 127 (2) ◽  
pp. 521-527 ◽  
Author(s):  
Haroon Khan ◽  
Muhammad Saeed ◽  
Anwal-Ul-Hassan Gilani ◽  
Murad Ali Khan ◽  
Ahsana Dar ◽  
...  
Keyword(s):  
Antinociceptive Activity ◽  
Polygonatum Verticillatum ◽  
Pain Models

scholarly journals Methanol Extract of Dicranopteris linearis Leaves Attenuate Pain via the Modulation of Opioid/NO-Mediated Pathway

Biomolecules ◽  
2020 ◽  
Vol 10 (2) ◽  
pp. 280 ◽  
Author(s):  
Zainul Amiruddin Zakaria ◽  
Rushduddin Al Jufri Roosli ◽  
Najihah Hanisah Marmaya ◽  
Maizatul Hasyima Omar ◽  
Rusliza Basir ◽  
...  
Keyword(s):  
Methanol Extract ◽  
Soluble Guanylyl Cyclase ◽  
Antinociceptive Activity ◽  
Opioid Antagonist ◽  
No Donor ◽  
Writhing Test ◽  
Thermal Nociception ◽  
Pain Models ◽  
Analgesic Agents ◽  
Dicranopteris Linearis

Dicranopteris linearis leaf has been reported to exert antinociceptive activity. The present study elucidates the possible mechanisms of antinociception modulated by the methanol extract of D. linearis leaves (MEDL) using various mouse models. The extract (25, 150, and 300 mg/kg) was administered orally to mice for 30 min priot to subjection to the acetic acid-induced writhing-, hot plate- or formalin-test to establish the antinociceptive profile of MEDL. The most effective dose was then used in the elucidation of possible mechanisms of action stage. The extract was also subjected to the phytochemical analyses. The results confirmed that MEDL exerted significant (p < 0.05) antinociceptive activity in those pain models as well as the capsaicin-, glutamate-, bradykinin- and phorbol 12-myristate 13-acetate (PMA)-induced paw licking model. Pretreatment with naloxone (a non-selective opioid antagonist) significantly (p < 0.05) reversed MEDL effect on thermal nociception. Only l-arginine (a nitric oxide (NO) donor) but not N(ω)-nitro-l-arginine methyl ester (l-NAME; a NO inhibitor) or 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; a specific soluble guanylyl cyclase inhibitor) significantly (p < 0.05) modified MEDL effect on the writhing test. Several polyphenolics and volatile antinociceptive compounds were detected in MEDL. In conclusion, MEDL exerted the opioid/NO-mediated antinociceptive activity, thus, justify D. linearis as a potential source for new analgesic agents development.

Antinociceptive Effects of Aza-Bicyclic Isoxazoline-Acylhydrazone Derivatives in Different Models of Nociception in Mice

2022 ◽  
Vol 22 ◽  
Author(s):  
Fernanda Virginia Barreto Mota ◽  
Felipe Neves Coutinho ◽  
Vanessa Mylenna Florêncio de Carvalho ◽  
Julyanne Cunha de Assis Correia ◽  
Isla Vanessa Gomes Alves Bastos ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Acetic Acid ◽  
Potassium Channels ◽  
Antinociceptive Activity ◽  
Writhing Test ◽  
Cholinergic Pathways ◽  
Chemical Models ◽  
Pain Models ◽  
Antinociceptive Effects ◽  
Adrenergic Systems

Background: In a study recently published by our research group, the compounds isoxazoline-acylhydrazone derivatives R-99 and R-123 presented promising antinociceptive activity. However, the mechanism of action of this compound is still unknown. Objective: This study aimed to assess the mechanisms involved in the antinociceptive activity of these compounds in chemical models of pain. Methods: Animals were orally pretreated and evaluated in the acetic acid-, formalin-, capsaicin-, carrageenan- and Complete Freund's Adjuvant (CFA)-induced pain models in mice. The effects of the compounds after pretreatment with naloxone, prazosin, yohimbine, atropine, L-arginine, or glibenclamide were studied, using the acetic acid-induced writhing test to verify the possible involvement of opioid, α1-adrenergic, α2-adrenergic or cholinergic receptors, and nitric oxide or potassium channels pathways, respectively. Results: R-99 and R-123 compounds showed significant antinociceptive activity on pain models induced by acetic acid, formalin, and capsaicin. Both compounds decreased the mechanical hyperalgesia induced by carrageenan or CFA in mice. The antinociceptive effects of R-99 and R-123 on the acetic acid-induced writhing test were significantly attenuated by pretreatment with naloxone, yohimbine or atropine. R-99 also showed an attenuated response after pretreatment with atropine and glibenclamide. However, on the pretreatment with prazosin, there was no change in the animals' response to both compounds. Conclusion: R-99 and R-123 showed antinociceptive effects related to mechanisms that involve, at least in part, interaction with the opioid and adrenergic systems and TRPV1 pathways. The compound R-99 also interacts with the cholinergic pathways and potassium channels.

Alleviation of pain and depression by specific neural transplants: Fine structural correlates

1992 ◽  
Vol 50 (2) ◽  
pp. 1066-1067
Author(s):  
George D. Pappas ◽  
Jacqueline Sagen
Keyword(s):  
Opioid Peptides ◽  
Chromaffin Cells ◽  
Pain Sensitivity ◽  
Opioid Peptide ◽  
Local Source ◽  
Pain Models ◽  
Neural Transplants ◽  
Adrenergic Antagonists ◽  
Csf Levels ◽  
Donor Source

We have been interested in the use of neural transplants mainly as a local source of neuroactive substances, rather than as a replacement for damaged neural circuities. In particular, we have been exploring the possibilities of reducing pain by transplants of opioid peptide producing cells, and reducing depression by transplants of monoamine-producing cells. For the past several years, work in our laboratory has demonstrated in both acute and chronic pain models that transplantation of adrenal medullary tissue or isolated chromaffin cells into CNS pain modulatory regions can reduce pain sensitivity in rodents. Chromaffin cells were chosen as donor source since they produce high levels of both opioid peptides and catecholamines, substances which independently, and probably synergistically, reduce pain sensitivity when injected locally into the spinal cord. The analgesia produced by these transplants most likely results from the release of both opioid peptides and catecholamines, since it can be blocked or attenuated by opiate or adrenergic antagonists, respectively. Furthermore, CSF levels of met-enkephalin and catecholamines are increased by the transplants.

Sign in / Sign up

Export Citation Format

Share Document